143 related articles for article (PubMed ID: 22367656)
1. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.
Fusar-Poli P; Berger G
J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656
[TBL] [Abstract][Full Text] [Related]
2. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
Fusar-Poli P; Kempton MJ; Rosenheck RA
Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
6. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
7. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of clozapine with a second antipsychotic - a meta-analysis.
Taylor DM; Smith L; Gee SH; Nielsen J
Acta Psychiatr Scand; 2012 Jan; 125(1):15-24. PubMed ID: 22077319
[TBL] [Abstract][Full Text] [Related]
9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression.
Sarris J; Mischoulon D; Schweitzer I
J Clin Psychiatry; 2012 Jan; 73(1):81-6. PubMed ID: 21903025
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD
J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754
[TBL] [Abstract][Full Text] [Related]
14. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
Welge JA; Keck PE
Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
[TBL] [Abstract][Full Text] [Related]
15. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
Berger GE; Proffitt TM; McConchie M; Yuen H; Wood SJ; Amminger GP; Brewer W; McGorry PD
J Clin Psychiatry; 2007 Dec; 68(12):1867-75. PubMed ID: 18162017
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
[TBL] [Abstract][Full Text] [Related]
17. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial.
Hamazaki K; Itomura M; Huan M; Nishizawa H; Sawazaki S; Tanouchi M; Watanabe S; Hamazaki T; Terasawa K; Yazawa K
Nutrition; 2005 Jun; 21(6):705-10. PubMed ID: 15925295
[TBL] [Abstract][Full Text] [Related]
18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
20. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review.
Heringa SM; Begemann MJ; Goverde AJ; Sommer IE
Schizophr Res; 2015 Nov; 168(3):603-13. PubMed ID: 25914107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
